Using either GlaxoSmithKline Plc’s Tyverb or Roche Holding AG’s Herceptin with another type of breast cancer treatment didn’t offer enough value to patients to justify the cost, the U.K. National Institute for Health and Clinical Excellence said.
The agency, known as NICE, made the comments today in draft guidance on the treatment of patients whose hard-to-treat breast cancer has spread.
via bloomberg.com
No comments:
Post a Comment